echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Myeloma 10 billion market stags, the original research drug frequency "de-tide"

    Myeloma 10 billion market stags, the original research drug frequency "de-tide"

    • Last Update: 2020-11-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On August 26, 2020, the Medical Blood Channel released the latest edition of the 2020 Guidelines for Multiple Myeloma in China.
    new combination therapy program, as well as the market of large molecule antibody drugs, to promote the domestic multi-risk myeloma treatment management level significantly improved, objectively has been fully in line with Western countries.
    nearly two years, the development of new drugs has made great progress, driven by the evaluation project of the quality and efficacy of generic drugs.
    In 2019, the National Drug Administration (NMPA) approved five multiple myeloma treatment drugs, namely, the Dharetoyu single anti-injection in Janssen-Cilag, Belgium, Zhengtian Qing Pharmaceuticals, Qilu Pharmaceuticals' Lanadamine Capsules, Nanjing Synthe Dongyuan, Nanjing Zhengda Tianqing's injection of boron zomi.
    From 2020 to the present, NMPA has approved four multiple myeloma treatment drugs, namely Suzhou Terry Pharmaceuticals, Zhengda Tianqing Pharmaceuticals, Stone Pharmaceuticals Group Ohi Pharmaceuticals' injection boron tezome, yangzijiang Pharmaceuticals Group's Lnadamine capsules.
    From 2019 to October 2020, NMPA approved multiple myeloma treatment drug multiple myeloma caused human concern in recent years, with the advent of new drugs, improved detection methods, as well as the rapid development of an aging society and the renewal of the concept of health of the elderly, people have a new understanding and attention to many low incidence of malignant tumors, thus promoting the rapid development of the new drug market for relapsed multiple myeloma.
    the latest edition of the 2020 China Multiple Myeloma Guide, the addition of Daleitoyu monoanti (CD38 monoanti) / lynadoamine / dexamisson (DRD), Daretoyu single resistance / boron The combined chemotherapy programmes of Zome/Tessemisson (DVD) and Daretoyu monoanti/Isazzomi/Disamisson (DID) open up new treatment models in the field of multiple myeloma and promote the integration of domestic and related therapeutic drugs with foreign countries.
    August 2020, Sanofi's Sarclisa and GlaxoSmithKline's Belenrep were approved for listing by the FDA.
    12 multiple myeloma treatments have been approved, and Idecabtagene vicleucel, developed by New Base, is in the BLA phase and is expected to be approved by the FDA in 2020.
    The world's most popular new drug for multiple myeloma treatments in the past five years, global sales of anti-multiple myeloma drugs exceeded $20.6 billion in 2019, up 13.16 percent from the previous year, according to multinational companies.
    has now formed a market pattern of competition between the eight major varieties of amine, daremu monoanti, pomadamine, boronitzomi, Kafezome, Isazzomi, irotoju monoanti and Plosafu.
    China's multiple myeloma market surfaced multiple myeloma (MM) is a middle-aged and elderly disease, the incidence rate in Western countries is slightly higher than in Asian countries, the average age of onset is over 70 years old.
    internationally recognized data show that the incidence of multiple myeloma in the United States is 7.1 per 100,000 men, 4.6 per 100,000 in women, and 4 per 100,000 in most developed countries and regions.
    incidence of multiple myeloma in China is about 2 to 3 per 100,000, which is the second largest malignant tumor of the blood system more than acute leukemia, and most patients are diagnosed in the middle and late stages.
    with the increasing aging of China's population and the gradual improvement of disease diagnosis technology, the total number of patients gradually surfaced, under reasonable treatment, it is imperative to improve the survival and quality of life of patients.
    Classic treatment plan clear boronitazome, lanadamine, cyclophosphamide, Changchun neo-alkali, dorobi star, carmostin, mephalus and dexamisund combination treatment plan, wherein boronitazome, lynadamine and salidamide is the combination of the basic drugs, can form a compound two, triple, four combination of the drug treatment.
    2020 Update of the China Multiple Myeloma Guidelines has improved existing cocktail therapies to improve patients' survival and quality of life.
    meters of intranet data show that in 2019, key provincial and municipal public hospitals terminal anti-tumor and immunomodulant sales market exceeded 45 billion yuan, an increase of 16.37 percent year-on-year, the sales scale of 14 treatment categories, showing the characteristics of rigid demand, including anti-myeloma TOP10 clinical drug market more than 2.3 billion yuan, an increase of 33.17 percent year-on-year.
    At present, the main drugs against myeloma are boronidazome, isazomi, lynadamine, salidamine, dorobis, umbenmeis, cisplatin, etoposide, Changchun neo-alkali, cyclophosphamide and compound drugs, the domestic myeloma treatment market is expected to exceed 10 billion yuan in 2020.
    boron zomi 7-1, the original research drug "Wanyu" proportion decline boron tazomy is the world's first protein enzyme targeted for treatment of cancer drugs.
    May 13, 2003, the FDA approved the listing of boratezomi injections for the treatment of multiple myeloma, the trade name Velcade.
    to quickly improve Velcade's sales performance, increase efforts to expand the U.S. market, the rest of the country's sales business entrusted to the U.S. Johnson and Johnson, Velade sales to date has exceeded $28 billion.
    in 2019, global sales of boron tazomethals were $1,874 million, down 19.61 percent from the previous year, despite increasing competition in the anti-myeloma market.
    The State Drug Administration approved Johnson and Johnson's boron tezomethmi for domestic listing on February 21, 2005, under the exclusive agency of Janssen-Cilag, with the product name Wan Wei; The first generic drug boron zomi injection was approved for the market, the commodity is named nitrate, thus breaking the exclusive monopoly of imported drugs situation; according to
    meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal borontzomi market size of nearly 1.5 billion yuan, of which public hospitals are the main sales market.
    in 2019 in key provinces and cities of public hospital terminal boron tezometh manufacturers competitive pattern, Janssen-Cilag's Wanyi accounted for 64.96 percent of the market share, Jiangsu Haussen's Yantai accounted for 21.71 % market share, Qilu's Qipler accounted for 7.51% of the market share, Zhengda Qing Pharmaceuticals' Chiping accounted for 5.66% of the market share, Nanjing Zhengtianqing's Yiyu accounted for 0.17% of the market share.
    with the approval of Nanjing Synong Dongyuan, Suzhou Terry and Shi Pharmaceutical Group's European-Italian products on the market, the market pattern of Boron titzomi will be reshaped again in 2020.
    to the leading MM market, the domestic 4-1 pattern of the formation of multiple myeloma another heavy treatment drug developed by the United States New Base Biopharmaceutical Company, the product was approved by the FDA on December 27, 2005, the trade name Revlimid, clinically used to treat multiple myeloma, myeloma syndrome and set cell lymphoma (MCL) and so on.
    so far, lynamamine has been approved for five adaptations and remains the world's gold standard drug for the treatment of multiple myeloma.
    In 2019, global sales of amines reached $10,832 million, up 11.84 percent from the previous year, making it the world's fourth-largest variety, behind Shumeile (Adamo Mono-Resistance), Alto (Apixaban) and Corinthian (Paboli-Pearl Mono-Resistance).
    On January 22, 2013, Celgene Europe Limited of the United Kingdom was approved for import of the amine capsule, a commodity called RuiFuMei, clinical studies confirmed that Refumei in the treatment of patients with multiple myeloma demonstrated high effectiveness and high safety, can effectively extend the survival of patients with multiple myeloma in China, and improve the quality of life of patients.
    in November 2017, Beijing Shuangju Pharmaceutical Co., D.A., the first copy of the amine capsules listed, the commodity name, and on June 28, 2020 passed a consistent evaluation.
    At present, there are four pharmaceutical companies in China to the nadamine approved production, of which Qilu Pharmaceuticals and Yangzijiang Pharmaceuticals to the nadamine capsules approved for the new classification of the market, as if through the consistent evaluation.
    public hospitals are still the main sales market for amines, with the market for end-to-end amines in China's public medical institutions exceeding 700 million yuan in 2019, up 79.46 percent from the previous year, and H1's growth rate reaching a new high in 2020, up 98.65 percent from the same period a year earlier, according to Minanet.
    in the first quarter of 2020, key provincial and municipal public hospital terminals to nada amine manufacturers competitive pattern, the original research drug Ruifumei accounted for 67.41% of the market share, Zhengda Qing's An Xian accounted for 16.86 percent With a market share of 8.49 percent, Qilu Pharmaceuticals' Qipuyi has a market share of 7.25 percent, and the market share of domestic drugs has increased significantly over the previous year, losing the market for the original drug.
    's lavish drug costs and market prospects are once again on the agenda of government executives, with the launch of new drugs for multiple myeloma treatments and the use of new cocktail therapies.
    is a good thing that the 2017 CD38 single anti-drug Daleitoyu monoantitic injection (commodity name Zhaoxuan) has been approved for sale in China, but sky-high medical costs are the frustration of most patients.
    In September 2020, D'Arretoyu monoanti (400mg/20ml) was quoted online for 19,000 yuan per unit, which would cost 236,400 yuan per year, even if the standard 4-week cycle for single-drug treatment.
    the clinically used boronitazome-lanadamine-desamisong treatment also makes many people look forward to the drug.
    3.5mg price of Velcade is around 14,000 yuan per course of treatment, which costs about 50,000 to 60,000 yuan per year.
    said that boronitazome and lynamamine were included in the national health insurance, the two drugs were reimbursed for only one, and the other was still at its own expense.
    into the health insurance before the monthly cost of Ruifumei about 50,000 yuan, in 2017 after the health insurance down to 231,000, Beijing Shuangyan Pharmaceuticals' first imitation of the amine capsule after the listing, the monthly cost of about 4000 yuan, for boronitazome and lanazomi and dexamison treatment program to say, the two main drugs choose a self-funded, 4000 yuan is still not a small expense.
    how to change the woes of patients with multiple myeloma is still an urgent issue.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.